search
Back to results

Prospective, Open Label Study to Assess 24hs IOP Recorded With Triggerfish® in Patients With OAG Before and After DSCI

Primary Purpose

Open Angle Glaucoma

Status
Terminated
Phase
Not Applicable
Locations
Switzerland
Study Type
Interventional
Intervention
contact lens sensor (CLS) SENSIMED Triggerfish®
Sponsored by
University Hospital, Geneva
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Open Angle Glaucoma

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Diagnosis of Open Angle Glaucoma (OAG) Documented glaucomatous Visual Field damage with MD more negative than -2 dB Progressing glaucomatous damage justifying a deep sclerectomy with collagen implant (DSCI) Aged ≥18 years, of either sex Not more than 6 diopters spherical equivalent on the study eye Have given written informed consent, prior to any investigational procedures Exclusion Criteria: • History of ocular surgery within the last 3 months on the study eye History of ocular laser treatment on the study eye Corneal or conjunctival abnormality precluding contact lens adaptation on the study eye Severe dry eye syndrome on the study eye Patients with allergy to corneal anesthetic Patients with contraindications for silicone contact lens wear Patients not able to understand the character and individual consequences of the investigation Participation in other clinical research within the last 4 weeks Any other contra-indication listed in the SENSIMED Triggerfish® user manual

Sites / Locations

  • University Hospital Geneva

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

contact lens sensor Triggerfish® in patients selected for deep sclerectomy with collagen implant

Arm Description

The contact lens sensor (CLS) SENSIMED Triggerfish® in will be placed on the study eye as selected for deep sclerectomy with collagen implant (DSCI)

Outcomes

Primary Outcome Measures

Changes between the nycthemeral IOP patterns recorded with TF during two 24-hour periods in patients with OAG
Nycthemeral IOP patterns differences will be evaluated with SENSIMED Triggerfish® recording for two 24hs periods in Open Angle Glaucoma patients comparing from baseline to 3 and 12 months

Secondary Outcome Measures

Changes in diurnal and nocturnal IOP patterns
Evaluation of the effect of deep sclerectomy with collagen implant (DSCI) on diurnal and nocturnal IOP patterns
Changes in visual field
Determination of changes in visual field
Number of Adverse Events
Evaluation of the safety and tolerability evaluation through the number of adverse effects

Full Information

First Posted
April 24, 2015
Last Updated
May 16, 2023
Sponsor
University Hospital, Geneva
search

1. Study Identification

Unique Protocol Identification Number
NCT05876936
Brief Title
Prospective, Open Label Study to Assess 24hs IOP Recorded With Triggerfish® in Patients With OAG Before and After DSCI
Official Title
A Prospective, Open Label Study to Assess the 24-hour Intraocular Pressure Pattern Recorded With Triggerfish® in Patients With Open Angle Glaucoma Before and After DSCI
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Terminated
Why Stopped
Principal investigator left the hospital
Study Start Date
December 2013 (undefined)
Primary Completion Date
July 2015 (Actual)
Study Completion Date
July 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University Hospital, Geneva

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
A prospective, open label study to assess the 24-hour intraocular pressure pattern recorded with SENSIMED Triggerfish® in patients with open angle glaucoma before and after deep sclerectomy with collagen implant
Detailed Description
This is a prospective, open label study to assess the 24-hour IOP pattern recorded by SENSIMED Triggerfish® in Open Angle Glaucoma (OAG) patients before and after deep sclerectomy with collagen implant (DSCI). After having signed and dated the patient informed consent form, patients will undergo an initial ophthalmic examination. The contact lens sensor (CLS) SENSIMED Triggerfish® will be placed on the study eye as selected for DSCI, for a baseline 24-hour IOP pattern recording session (S1), within 7 days preceding the surgical procedure. Patients will remain ambulatory and will be encouraged to follow a schedule as close to his/her usual lifestyle as possible. A patient diary will be distributed for the capture of patient activities during the IOP pattern recording. Upon completion of S1, the contact lens sensor (CLS) SENSIMED Triggerfish® will be removed and a final ophthalmic examination will be conducted. The patient diary will be collected and concomitant medication will be reported. The surgery will be scheduled within 2 days following S1. Unless contraindicated (e.g. large filtering bleb precluding placement of the contact lens sensor (CLS) SENSIMED Triggerfish®), patients will undergo a second 24-hour contact lens sensor (CLS) SENSIMED Triggerfish® IOP pattern recording session (S2) on the study eye 3 months after the surgical procedure. S2 will start at the same time of day ± 30 min as S1, preferably at a time that allows for sufficient recording of the wake-to-sleep and the sleep-to-wake phases. Prior to S2 and upon completion of thereof, ophthalmic examinations will be conducted and patient diary will be collected. In addition, any specifics regarding the DSCI and medication will be reported. A visual field (VF) assessment will also be performed to evaluate the changes after deep sclerectomy with collagen implant. Patients will undergo a third 24-hour SENSIMED Triggerfish® IOP pattern recording session (S3) on the study eye 12 months after the surgical procedure. S3 will start at the same time of day ± 30 min as S2, preferably at a time that allows for sufficient recording of the wake-to-sleep and the sleep-to-wake phases. Prior to S3 and upon completion of thereof, ophthalmic examinations will be conducted and patient diary will be collected. In addition, any specifics regarding the deep sclerectomy with collagen implant (DSCI) and medication will be reported. A visual field assessment will also be performed to evaluate the changes after deep sclerectomy with collagen implant (DSCI).This concludes the study for the patients. Hence, the overall study duration for the patient is limited to 13 months. The study has been planned to recruit at least 40 eligible patients within 11 months from initiation. Hence the overall study duration from the first patient accrued into the study until last patient out equates to about 24 months or less. Allowing for a database lock within 4 weeks of study completion, a preliminary statistical report on the primary efficacy endpoint is foreseen within 2 weeks thereafter.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Open Angle Glaucoma

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
5 (Actual)

8. Arms, Groups, and Interventions

Arm Title
contact lens sensor Triggerfish® in patients selected for deep sclerectomy with collagen implant
Arm Type
Other
Arm Description
The contact lens sensor (CLS) SENSIMED Triggerfish® in will be placed on the study eye as selected for deep sclerectomy with collagen implant (DSCI)
Intervention Type
Device
Intervention Name(s)
contact lens sensor (CLS) SENSIMED Triggerfish®
Intervention Description
contact lens sensor CLS placing and fitting evaluation, 24h recording
Primary Outcome Measure Information:
Title
Changes between the nycthemeral IOP patterns recorded with TF during two 24-hour periods in patients with OAG
Description
Nycthemeral IOP patterns differences will be evaluated with SENSIMED Triggerfish® recording for two 24hs periods in Open Angle Glaucoma patients comparing from baseline to 3 and 12 months
Time Frame
Baseline, 3 months and 12 months
Secondary Outcome Measure Information:
Title
Changes in diurnal and nocturnal IOP patterns
Description
Evaluation of the effect of deep sclerectomy with collagen implant (DSCI) on diurnal and nocturnal IOP patterns
Time Frame
3 months and 12 months after deep sclerectomy with collagen implant (DSCI)
Title
Changes in visual field
Description
Determination of changes in visual field
Time Frame
3 months and 12 months after deep sclerectomy with collagen implant (DSCI)
Title
Number of Adverse Events
Description
Evaluation of the safety and tolerability evaluation through the number of adverse effects
Time Frame
3 months and 12 months after deep sclerectomy with collagen implant (DSCI)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diagnosis of Open Angle Glaucoma (OAG) Documented glaucomatous Visual Field damage with MD more negative than -2 dB Progressing glaucomatous damage justifying a deep sclerectomy with collagen implant (DSCI) Aged ≥18 years, of either sex Not more than 6 diopters spherical equivalent on the study eye Have given written informed consent, prior to any investigational procedures Exclusion Criteria: • History of ocular surgery within the last 3 months on the study eye History of ocular laser treatment on the study eye Corneal or conjunctival abnormality precluding contact lens adaptation on the study eye Severe dry eye syndrome on the study eye Patients with allergy to corneal anesthetic Patients with contraindications for silicone contact lens wear Patients not able to understand the character and individual consequences of the investigation Participation in other clinical research within the last 4 weeks Any other contra-indication listed in the SENSIMED Triggerfish® user manual
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kaweh Mansouri, Dr MD
Organizational Affiliation
Univeresity Hospital Geneva
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Hospital Geneva
City
Geneva
Country
Switzerland

12. IPD Sharing Statement

Learn more about this trial

Prospective, Open Label Study to Assess 24hs IOP Recorded With Triggerfish® in Patients With OAG Before and After DSCI

We'll reach out to this number within 24 hrs